TMO Thermo Fisher Scientific
Healthcare · Measuring & Controlling Devices, Nec
Thermo Fisher Scientific (TMO) is a healthcare company in the Measuring & Controlling Devices, Nec industry, with a market capitalization of $172.7 billion. Shares last traded at $464.76, 27.8% below their 52-week high. Over the past year the stock is up 19.0%. TMO trades at a price-to-earnings ratio of 25.70, below the Measuring & Controlling Devices, Nec median of 43.85. Net profit margin is 15.1%, above the peer median of 10.4%. Revenue grew 3.9% year over year. The shares yield 0.6% in dividends.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | $4.43 | 2026-05-01 |
| FY 2025 | $17.74 | 2026-02-26 |
| Q3 2025 | $12.53 | 2025-10-31 |
| Q2 2025 | $8.26 | 2025-08-01 |
| Q1 2026 | $3.98 | 2026-05-01 |
| FY 2025 | $16.53 | 2026-02-26 |
Measuring & Controlling Devices, Nec peers
TMO vs 11 industry peers (Measuring & Controlling Devices, Nec), by market cap.
| TMO | Thermo Fisher Scientific | $172.7B | 25.70 | 3.88 | 15.1% | +0.67% |
| ROK | Rockwell Automation | $52.7B | 60.69 | 6.32 | 10.4% | +3.29% |
| ONTO | Onto Innovation Inc. | $16.6B | 121.38 | 16.51 | 13.6% | +4.60% |
| TRMB | Trimble Inc. | $11.5B | 27.01 | 3.19 | 11.8% | +0.54% |
| MIR | Mirion Technologies, Inc. | $4.6B | 158.01 | 4.92 | 3.1% | +5.38% |
| MASS | 908 Devices Inc. | $335M | 17.19 | 5.96 | 34.7% | +3.14% |
| QSI | Quantum-Si Inc | $214M | -2.11 | — | — | +6.10% |
| OWLT | Owlet, Inc. | $145M | -3.65 | 1.37 | -37.5% | +6.95% |
| GEOS | GEOSPACE TECHNOLOGIES CORP | $93M | -9.60 | 0.84 | -8.8% | -0.07% |
| BCHT | Birchtech Corp. | $61M | -20.08 | 3.45 | -17.2% | +14.93% |
| APM | Aptorum Group Ltd | — | — | — | — | -2.92% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.